|
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Asprosin was first reported in 2016 as a fasting-induced protein hormone that modulates hepatic glucose. It is released as the C-terminal cleavage product of profibrillin (P35555). It is secreted by white adipose, circulates at nanomolar levels, and is recruited to the liver, where it activates the G protein-cAMP-PKA pathway, resulting in rapid glucose release into the circulation. The molecular mechanism is unknown but it is suggested asprosin uses a cell-surface receptor system distinct from those used by glucagon and catecholamines [3]. A study published in 2017 suggests that in addition to performing a glucogenic function, asprosin is a centrally acting orexigenic hormone that is a potential therapeutic target in the treatment of both obesity and diabetes [2]. The authors have also filed a patent claiming the potential use of asprosin (or an antobody or inhibitor of asprosin) for the maintenance of optimal body weight and blood glucose [1].
Species: Human
|
| References |
|
1. Atul Chopra, David D. Moore. (2015)
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose. Patent number: WO2015084625 A1. Priority date: 11/06/2015. Publication date: 02/12/2013. |
|
2. Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M et al.. (2017)
Asprosin is a centrally acting orexigenic hormone. Nat Med, 23 (12): 1444-1453. [PMID:29106398] |
|
3. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B et al.. (2016)
Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell, 165 (3): 566-79. [PMID:27087445] |
